Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line erlotinib versus first-line cisplatin + gemcitabine with crossover to the alternate regimen in advanced non-small cell lung cancer
2005-005968-90Phase 3Completed
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of erlotinib, cisplatin and gemcitabine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Overall survival. Started Jul 2007; status: completed.
02
Drugs
erlotinibcisplatingemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-005968-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005968-90.